Ghadjar P, Hayoz S, Bernhard J, et al. - From a randomized, multicenter, phase 3 trial (SAKK 09/10), the results of comparison between conventional and dose-intensified salvage radiotherapy (SRT) for men with biochemical progression of prostate cancer following radical prostatectomy (RP), were described herein. Patients were randomized to conventional-dose (64 Gy) or dose-intensified SRT (70 Gy) to the prostate bed without hormonal therapy. Following median follow-up of 6.2 yr, the median freedom from biochemical progression (FFBP) was identified to be 8.2 yr in the 64 Gy arm and 7.6 in the 70 Gy arm, with a hazard ratio of 1.14. The estimated 6-year FFBP rates were 62% and 61%, respectively. In terms of clinical progression-free survival, time to hormonal treatment, or overall survival, there were no significant differences. No significant differences were observed in quality of life. In the light of these observations, conventional-dose SRT to the prostate bed was concluded to be sufficient in cases with early biochemical progression of prostate cancer post-RP.